| Centers | ||
| EU-OPENSCREEN | VMCC, University of Michigan | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | 
| EU-OPENSCREEN is a multinational, not-for-profit initiative, which 
integrates high-capacity screening platforms and chemistry groups across
 Europe. The aim of this initiative is to support individual scientists 
interested in chemical  biology... | The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... | Chulalongkorn
 Drug Discovery and Drug Development Research Center (Chula4DR) was 
established in 2017, with the aim to facilitate advancement of academic 
drug discovery and drug development research by leveraging innovations 
and  sciences...Read more | 
| Partnerships | Events | Jobs | 
| UCSF And Genentech to Develop Drugs to Treat Neurodegenerative DiseasesUniversity of California, San Francisco (UCSF) and Genetech have entered into a research collaboration to develop drugs to treat neurodegenerative diseases. Genetech will be providing funding to researchers at UCSF Small Molecule Discovery Center... View all Research collaboration and license agreementThe University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon... View all Pfizer's CTI Establishes New Partnership with UCSFPfizer's Center for Therapeutic Innovation has established a new multi-year research and development partnership with University of California, San Francisco (UCSF). Pfizer will provide $85 million in research and milestone payments over five year... View all | No EVENTS for listing | No Job Posts | 



 
								 
								 
								 
						 		
								 
								
								 
								
								 
								
								 
								
								 
								
								 
								
								